Ref ID: 19210
Author:
M. Gomes*, V. Mulanovich, J. Ying, R. Lewis, D. Kontoyiannis
Author address:
Houston, US
Full conference title:
23rd European Congress of Clinical Microbiology and
Infectious Diseases
Date: 27 April 2014
Abstract:
Objectives: We aimed to investigate risk factors for documented (definite or probable, according to revised EORTC definitions) invasive fungal infections (IFIs) in acute myeloid leukemia (AML) patients. Methods: We conducted a nested case-control study in a cohort of 165 patients older than 18 years old newly diagnosed with AML who received primary antifungal prophylaxis (PAP) during 120 days after first induction chemotherapy in M.D. Anderson Cancer Center from August 2009 to March 2011. We excluded patients who underwent stem cell transplant (13 patients), were never admitted to the hospital (4 patients), used fluconazole only as PAP (12 patients) or those who had presumed IFI (13 patients) during the study period. We found 21 patients with documented IFI (4 definite mold and 4 yeast infections, 1 coccidioidomycosis and 12 probable invasive aspergillosis) (case group). The control group included 104 patients without an IFI. Variables investigated as factors associated with IFI were gathered from the period prior to the date that IFI was first detected in case patients or as the entire period of following up for the control patients. Thirty and 21 variables were investigated as risk factors at 120 and 42 days study period, respectively. Results: The Table shows the Cox regression models for IFIs with PAP drug, neutropenia and complete remission as time-dependent variables in the analyses at 42 and 120 day-study period. Conclusions: This retrospective single center study indicates that patients with therapy related AML should be more closely monitored for IFI. Echinocandin-based PAP should be avoided or used with caution in AML population. Further studies should evaluate the relevance and biologic plausibility of appendectomy for IFI risk in leukemia.
Abstract Number: P1002
Conference Year: 2013
Link to conference website: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=167284&XNSPRACHE_ID=2&XNKONGRESS_ID=180&XNMASK
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a